Cargando…
Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study
SIMPLE SUMMARY: This research aimed to study the effectiveness and safety of a drug called abemaciclib in patients with metastatic breast cancer (MBC) who had previously received similar treatments. The medical records of 11 patients who were given abemaciclib after their disease worsened despite pr...
Autores principales: | de Luna Aguilar, Alicia Milagros, Fuentes, Javier David Benitez, Ortega Anselmi, Justo, Olalla Inoa, Jennifer, Flores Navarro, Paloma, Lopez de Sá, Alfonso, Fuentes Antras, Jesus, Rodríguez Rey, Cristina, Ortega Candil, Aída, Moreno Antón, Fernando, García Sáenz, Jose Ángel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526325/ https://www.ncbi.nlm.nih.gov/pubmed/37760421 http://dx.doi.org/10.3390/cancers15184452 |
Ejemplares similares
-
Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia
por: Fuentes-Antrás, Jesús, et al.
Publicado: (2020) -
Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy
por: Gharbi, Severine Isabelle, et al.
Publicado: (2022) -
Malignant Melanoma
por: Ortega Candil, Aída, et al.
Publicado: (2012) -
Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas
por: Liang, Muh-Lii, et al.
Publicado: (2020) -
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)